(Q43687453)

25 November 2017

title

Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study (English)

1 reference

25 November 2017

1 reference

1

1 reference

25 November 2017

B Kilhovd

2

1 reference

25 November 2017

I Lager

3

1 reference

25 November 2017

P Mustajoki

4

1 reference

25 November 2017

A Dejgaard

5

1 reference

25 November 2017

Scandinavian Repaglinide Group

6

1 reference

25 November 2017

publication date

1 May 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

18

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

395-401

1 reference

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Repaglinide versus glyburide: a one-year comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00490.X

10.1046/J.1464-5491.2001.00490.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference